Monocyte (macrophage)-specific antibodies in patients with systemic lupus erythematosus (SLE)

Circulating monocyte (macrophage)-specific antibodies in patients with autoimmune thyroid diseases

We investigated the presence of circulating monocyte-specific antibodies (monocytotoxic activities) by a complement-dependent cytotoxicity test and the relations between these monocytotoxic activities and other immunological indices in patients with autoimmune thyroid diseases. Antibodies reactive for monocytes (macrophages) were found in the sera from patients with autoimmune thyroid diseases. These antibodies were present in both IgG and IgM fractions and specific for monocytes since they were absorbed by monocytes but not by lymphocytes or granulocytes; furthermore, lymphocytotoxic and granulocytotoxic activities were not changed after the absorption of the sample sera by monocytes. Also, these antibodies did not have cross-reactivity to thyroid-specific antigens demonstrated by absorption tests and their specificity was different from anti HLA-DR antibody demonstrated by a flow cytofluorometric analysis. Monocyte-specific antibodies are reactive for autologous monocytes as well as allogenic monocytes. Patients who had positive monocytotoxic activities had high levels of TSH receptor antibodies (TRAb) and antimicrosomal antibodies in Graves' disease, and monocytotoxic activities were significantly correlated with the levels of TRAb in Graves' disease. These results suggest that the monocyte-specific antibodies (monocytotoxic activities) were significantly correlated with the immunological activities in Graves' disease.

Systemic lupus erythematosus sera inhibit antigen presentation by macrophages to T cells

Several reports have demonstrated that systemic lupus erythematosus (SLE) patients have a decreased response to exogenous antigens both in vivo and in vitro. We examined the effects of SLE sera on macrophage (M phi) antigen-presenting functions. M phi from normal donors were pulsed with tetanus toxoid antigen in the presence of SLE or normal human serum (NHS), fixed in paraformaldehyde, and incubated with autologous T cells. Of 16 SLE sera tested, 11 inhibited the T-cell proliferative response (measured by [3H]thymidine uptake) compared to control NHS; mean percentage inhibition was 53 +/- 23%. This inhibition did not result from interference with antigen uptake by M phi and was found in both IgM and IgG fractions of the sera. There was a positive correlation between the amount of inhibition and the cytotoxic reactivity of the SLE sera against M phi as measured by Terasaki assay (r = 0.659, P less than 0.01). However, the presence and the amount of the inhibition did not correlate with serum immune complexes by Clq ELISA, serum anti-DR antibodies, or clinical disease activity of the SLE patients. We conclude that some SLE sera possess IgM and IgG antibodies reactive with M phi which affect M phi antigen-presenting functions, and might relate to decreased antigenic response in SLE patients.